These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22120718)

  • 1. IDH mutation status in prostate cancer.
    Ghiam AF; Cairns RA; Thoms J; Dal Pra A; Ahmed O; Meng A; Mak TW; Bristow RG
    Oncogene; 2012 Aug; 31(33):3826. PubMed ID: 22120718
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
    Yen KE; Bittinger MA; Su SM; Fantin VR
    Oncogene; 2010 Dec; 29(49):6409-17. PubMed ID: 20972461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.
    Brat DJ; Cagle PT; Dillon DA; Hattab EM; McLendon RE; Miller MA; Buckner JC;
    Arch Pathol Lab Med; 2015 Sep; 139(9):1087-93. PubMed ID: 25642959
    [No Abstract]   [Full Text] [Related]  

  • 4. CNS cancer: Breaking boundaries - IDH mutations in glioma.
    Killock D
    Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26787277
    [No Abstract]   [Full Text] [Related]  

  • 5. IDH1 mutation detection by droplet digital PCR in glioma.
    Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
    Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
    Kickingereder P; Sahm F; Radbruch A; Wick W; Heiland S; Deimling Av; Bendszus M; Wiestler B
    Sci Rep; 2015 Nov; 5():16238. PubMed ID: 26538165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
    Brat DJ; Aldape K; Colman H; Holland EC; Louis DN; Jenkins RB; Kleinschmidt-DeMasters BK; Perry A; Reifenberger G; Stupp R; von Deimling A; Weller M
    Acta Neuropathol; 2018 Nov; 136(5):805-810. PubMed ID: 30259105
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical molecular pathologic diagnosis of infiltrating gliomas.
    Pekmezci M; Perry A
    Surg Pathol Clin; 2015 Mar; 8(1):49-61. PubMed ID: 25783821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Horbinski C
    Neuro Oncol; 2015 Mar; 17(3):478-9. PubMed ID: 25605815
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
    Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 17. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of recently described genetic alterations in central nervous system tumors.
    Lucas CG; Solomon DA; Perry A
    Hum Pathol; 2020 Feb; 96():56-66. PubMed ID: 31678207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.